1. Streamlining the transition of biological products (a) Continued review of certain applications Section 7002(e)(4)(B) of the Biologics Price Competition and Innovation Act of 2009 ( Public Law 111–148 ) is amended— (1) by striking clauses (i), (ii), and (vi); and (2) by inserting before clause (iii) the following: (i) In general With respect to an application for a biological product submitted under subsection (b) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) that is filed not later than March 23, 2019, and that is pending (or tentatively approved) as of March 23, 2020— (I) the Secretary shall continue to review such application under such section 505, even if such review continues after March 23, 2020; and (II) upon approval of such application, such application shall be deemed to be a license for the biological product under section 351 of the Public Health Service Act, pursuant to subparagraph (A), and any period of exclusivity, as applicable, shall be determined in accordance with such section. (ii) Treatment of listed drugs With respect to a drug that is a biological product that has been deemed licensed under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ) pursuant to subparagraph (A) and that is referenced in an application described in clause (i), such drug shall— (I) continue to be identified as a listed drug on the list published pursuant to section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act, and the information for such drug on such list shall not be revised (or removed) unless and until the date on which each application described in clause (i) that references such drug is— (aa) no longer pending review (or the approval of such drug is tentative) under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ); or (bb) removed from such list in accordance with subparagraph (C) of such section 505(j)(7)